Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference — Sep 30th, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announce...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 — Oct 21st, 2024

Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds — Oct 15th, 2024

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher Ret...

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin — Oct 16th, 2024

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatili...